A 2025 meta-analysis (a study that pools data from multiple trials to find patterns) confirmed this ranking, with retatrutide showing a mean difference of -16.34 kg vs tirzepatide's -11.82 kg vs placebo (J Endocrine Soc, 2025)
Specific statistics can be found in the corresponding figure legends
Next, providers can explain how human research differs and summarize the available human evidence on GLP-1 drugs and thyroid cancer risk
The drug is also meant to assist overweight adults who also have weight-related conditions, such as high blood pressure, high cholesterol, or Type 2 diabetes, to lose weight
The ideal candidate will also have a healthy endocrine system, not be pregnant or breastfeeding, and have no history of severe low blood sugar
No safety issues emerged [87]